Loading clinical trials...
Loading clinical trials...
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET)
Conditions
Interventions
Insulin detemir
Dietary regimen
Locations
112
United States
Novo Nordisk Investigational Site
Birmingham, Alabama, United States
Novo Nordisk Investigational Site
Ozark, Alabama, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Burlingame, California, United States
Novo Nordisk Investigational Site
Concord, California, United States
Novo Nordisk Investigational Site
Fullerton, California, United States
Start Date
October 29, 2010
Primary Completion Date
November 1, 2011
Completion Date
November 14, 2011
Last Updated
May 1, 2017
NCT05398783
NCT07224321
NCT07395050
NCT01399385
NCT07536516
NCT07232537
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions